

Immune Check Point Inhibitor-Europe Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/IB3866E56AEEN.html>

Date: December 2017

Pages: 142

Price: US\$ 3,480.00 (Single User License)

ID: IB3866E56AEEN

Abstracts

Report Summary

Immune Check Point Inhibitor-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Immune Check Point Inhibitor industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole Europe and Regional Market Size of Immune Check Point Inhibitor 2013-2017, and development forecast 2018-2023

Main market players of Immune Check Point Inhibitor in Europe, with company and product introduction, position in the Immune Check Point Inhibitor market

Market status and development trend of Immune Check Point Inhibitor by types and applications

Cost and profit status of Immune Check Point Inhibitor, and marketing status

Market growth drivers and challenges

The report segments the Europe Immune Check Point Inhibitor market as:

Europe Immune Check Point Inhibitor Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Germany

United Kingdom

France

Italy

Spain

Benelux

Russia

Europe Immune Check Point Inhibitor Market: Product Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

CTLA 4

PD 1

Others

Europe Spain Immune Check Point Inhibitor Market: Application Segment Analysis
(Consumption Volume and Market Share 2013-2023; Downstream Customers and
Market Analysis)

Medical Care

Experiment

Others

Europe Immune Check Point Inhibitor Market: Players Segment Analysis (Company and
Product introduction, Immune Check Point Inhibitor Sales Volume, Revenue, Price and
Gross Margin):

Advaxis

Agenus

Amgen

Bristol Myers Squibb

Faron Pharmaceuticals

Genentech

Genocea

Incyte Corporation

Innate Pharma

Kite Pharma

MacroGenics

Merck

NewLink Genetics Corp

Sorrento Therapeutics

TG Therapeutics

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF IMMUNE CHECK POINT INHIBITOR

- 1.1 Definition of Immune Check Point Inhibitor in This Report
- 1.2 Commercial Types of Immune Check Point Inhibitor
 - 1.2.1 CTLA
 - 1.2.2 PD
 - 1.2.3 Others
- 1.3 Downstream Application of Immune Check Point Inhibitor
 - 1.3.1 Medical Care
 - 1.3.2 Experiment
 - 1.3.3 Others
- 1.4 Development History of Immune Check Point Inhibitor
- 1.5 Market Status and Trend of Immune Check Point Inhibitor 2013-2023
 - 1.5.1 Europe Immune Check Point Inhibitor Market Status and Trend 2013-2023
 - 1.5.2 Regional Immune Check Point Inhibitor Market Status and Trend 2013-2023

CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Immune Check Point Inhibitor in Europe 2013-2017
- 2.2 Consumption Market of Immune Check Point Inhibitor in Europe by Regions
 - 2.2.1 Consumption Volume of Immune Check Point Inhibitor in Europe by Regions
 - 2.2.2 Revenue of Immune Check Point Inhibitor in Europe by Regions
- 2.3 Market Analysis of Immune Check Point Inhibitor in Europe by Regions
 - 2.3.1 Market Analysis of Immune Check Point Inhibitor in Germany 2013-2017
 - 2.3.2 Market Analysis of Immune Check Point Inhibitor in United Kingdom 2013-2017
 - 2.3.3 Market Analysis of Immune Check Point Inhibitor in France 2013-2017
 - 2.3.4 Market Analysis of Immune Check Point Inhibitor in Italy 2013-2017
 - 2.3.5 Market Analysis of Immune Check Point Inhibitor in Spain 2013-2017
 - 2.3.6 Market Analysis of Immune Check Point Inhibitor in Benelux 2013-2017
 - 2.3.7 Market Analysis of Immune Check Point Inhibitor in Russia 2013-2017
- 2.4 Market Development Forecast of Immune Check Point Inhibitor in Europe 2018-2023
 - 2.4.1 Market Development Forecast of Immune Check Point Inhibitor in Europe 2018-2023
 - 2.4.2 Market Development Forecast of Immune Check Point Inhibitor by Regions 2018-2023

CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES

3.1 Whole Europe Market Status by Types

3.1.1 Consumption Volume of Immune Check Point Inhibitor in Europe by Types

3.1.2 Revenue of Immune Check Point Inhibitor in Europe by Types

3.2 Europe Market Status by Types in Major Countries

3.2.1 Market Status by Types in Germany

3.2.2 Market Status by Types in United Kingdom

3.2.3 Market Status by Types in France

3.2.4 Market Status by Types in Italy

3.2.5 Market Status by Types in Spain

3.2.6 Market Status by Types in Benelux

3.2.7 Market Status by Types in Russia

3.3 Market Forecast of Immune Check Point Inhibitor in Europe by Types

CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Immune Check Point Inhibitor in Europe by Downstream Industry

4.2 Demand Volume of Immune Check Point Inhibitor by Downstream Industry in Major Countries

4.2.1 Demand Volume of Immune Check Point Inhibitor by Downstream Industry in Germany

4.2.2 Demand Volume of Immune Check Point Inhibitor by Downstream Industry in United Kingdom

4.2.3 Demand Volume of Immune Check Point Inhibitor by Downstream Industry in France

4.2.4 Demand Volume of Immune Check Point Inhibitor by Downstream Industry in Italy

4.2.5 Demand Volume of Immune Check Point Inhibitor by Downstream Industry in Spain

4.2.6 Demand Volume of Immune Check Point Inhibitor by Downstream Industry in Benelux

4.2.7 Demand Volume of Immune Check Point Inhibitor by Downstream Industry in Russia

4.3 Market Forecast of Immune Check Point Inhibitor in Europe by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF IMMUNE CHECK POINT INHIBITOR

5.1 Europe Economy Situation and Trend Overview

5.2 Immune Check Point Inhibitor Downstream Industry Situation and Trend Overview

CHAPTER 6 IMMUNE CHECK POINT INHIBITOR MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE

6.1 Sales Volume of Immune Check Point Inhibitor in Europe by Major Players

6.2 Revenue of Immune Check Point Inhibitor in Europe by Major Players

6.3 Basic Information of Immune Check Point Inhibitor by Major Players

6.3.1 Headquarters Location and Established Time of Immune Check Point Inhibitor Major Players

6.3.2 Employees and Revenue Level of Immune Check Point Inhibitor Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 IMMUNE CHECK POINT INHIBITOR MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Advaxis

7.1.1 Company profile

7.1.2 Representative Immune Check Point Inhibitor Product

7.1.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Advaxis

7.2 Agenus

7.2.1 Company profile

7.2.2 Representative Immune Check Point Inhibitor Product

7.2.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Agenus

7.3 Amgen

7.3.1 Company profile

7.3.2 Representative Immune Check Point Inhibitor Product

7.3.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Amgen

7.4 Bristol Myers Squibb

- 7.4.1 Company profile
- 7.4.2 Representative Immune Check Point Inhibitor Product
- 7.4.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Bristol Myers Squibb
- 7.5 Faron Pharmaceuticals
 - 7.5.1 Company profile
 - 7.5.2 Representative Immune Check Point Inhibitor Product
 - 7.5.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Faron Pharmaceuticals
- 7.6 Genentech
 - 7.6.1 Company profile
 - 7.6.2 Representative Immune Check Point Inhibitor Product
 - 7.6.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Genentech
- 7.7 Genocera
 - 7.7.1 Company profile
 - 7.7.2 Representative Immune Check Point Inhibitor Product
 - 7.7.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Genocera
- 7.8 Incyte Corporation
 - 7.8.1 Company profile
 - 7.8.2 Representative Immune Check Point Inhibitor Product
 - 7.8.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Incyte Corporation
- 7.9 Innate Pharma
 - 7.9.1 Company profile
 - 7.9.2 Representative Immune Check Point Inhibitor Product
 - 7.9.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Innate Pharma
- 7.10 Kite Pharma
 - 7.10.1 Company profile
 - 7.10.2 Representative Immune Check Point Inhibitor Product
 - 7.10.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Kite Pharma
- 7.11 MacroGenics
 - 7.11.1 Company profile
 - 7.11.2 Representative Immune Check Point Inhibitor Product
 - 7.11.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of MacroGenics

7.12 Merck

7.12.1 Company profile

7.12.2 Representative Immune Check Point Inhibitor Product

7.12.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Merck

7.13 NewLink Genetics Corp

7.13.1 Company profile

7.13.2 Representative Immune Check Point Inhibitor Product

7.13.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of NewLink Genetics Corp

7.14 Sorrento Therapeutics

7.14.1 Company profile

7.14.2 Representative Immune Check Point Inhibitor Product

7.14.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Sorrento Therapeutics

7.15 TG Therapeutics

7.15.1 Company profile

7.15.2 Representative Immune Check Point Inhibitor Product

7.15.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of TG Therapeutics

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF IMMUNE CHECK POINT INHIBITOR

8.1 Industry Chain of Immune Check Point Inhibitor

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF IMMUNE CHECK POINT INHIBITOR

9.1 Cost Structure Analysis of Immune Check Point Inhibitor

9.2 Raw Materials Cost Analysis of Immune Check Point Inhibitor

9.3 Labor Cost Analysis of Immune Check Point Inhibitor

9.4 Manufacturing Expenses Analysis of Immune Check Point Inhibitor

CHAPTER 10 MARKETING STATUS ANALYSIS OF IMMUNE CHECK POINT INHIBITOR

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference

I would like to order

Product name: Immune Check Point Inhibitor-Europe Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/IB3866E56AEEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IB3866E56AEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970